摘要
目的观察分析多西紫杉醇联合替吉奥在治疗蒽环类耐药三阴性乳腺癌(triple-negtive breast cancer,TNBC)中的临床疗效。方法选择2009年6月~2011年6月绍兴市人民医院肿瘤放疗科收治的64例三阴性乳腺癌患者,回顾性分析上述病例的临床资料,所有患者使用蒽环类药物治疗无效或复发,继而选择联合多西紫杉醇、替吉奥治疗,观察分析此种方案的临床疗效和不良反应情况。结果 64例患者的治疗后有效率为54.69%,病情控制率为79.69%,治疗过程中未见死亡病例,主要不良反应为胃肠道反应和骨髓抑制,但患者对此均可耐受;随访结果显示中位疾病进展时间为10.5个月,2年后无疾病进展生存率为0。结论联合多西紫杉醇、替吉奥治疗蒽环类耐药三阴性乳腺癌的临床效果良好,不良反应相对较轻,是较为理想的辅助化疗方案。
Objective To observe and analyze the clinical efficacy of docetaxel and S-1 in treatment of anthracycline-resistant triple-negtive breast cancer(TNBC).Methods 64 cases with TNBC admitted in People'' Hospital of Shaoxing City from June 2009 to June 2011were selected as research object.The clinical data of these cases were analyzed retrospectively.Anthracycline had been used to treat the cases, but with no effect or recurrence.Then docetaxel combined with S-1 was applied to the cases.Clinical efficacy and adverse reactions of the chemotherapy were observed and analyzed. Results After treatment,the efficiency of 64 cases was 54.69%,and the disease control rate was 79.69%.During the treatment,the main adverse reactions were gastrointestinal reactions and bone marrow suppression,without death,and patients could tolerate the adverse event.Follow-up results showed that the median time of progression was 10.5 months.After two years,progression-free survival rate was 0.Conclusion Docetaxel combined with S-1 has good clinical efficacy for anthracycline-resistant triple-negtive breast cancer,with relatively mild side effects,which may be an ideal adjuvant chemotherapy method.
出处
《中国生化药物杂志》
CAS
北大核心
2014年第3期116-118,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省医药卫生平台骨干人才计划(2011RCA015)
